CO4950621A1 - Peptidos mimeticos (pirazolon-piperidinas) liberadores de la hormona del crecimiento y sus usos en el tratamiento de la resistencia a la insulina - Google Patents
Peptidos mimeticos (pirazolon-piperidinas) liberadores de la hormona del crecimiento y sus usos en el tratamiento de la resistencia a la insulinaInfo
- Publication number
- CO4950621A1 CO4950621A1 CO98036379A CO98036379A CO4950621A1 CO 4950621 A1 CO4950621 A1 CO 4950621A1 CO 98036379 A CO98036379 A CO 98036379A CO 98036379 A CO98036379 A CO 98036379A CO 4950621 A1 CO4950621 A1 CO 4950621A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- group
- optionally
- cycloalkyl
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 102000018997 Growth Hormone Human genes 0.000 title 1
- 108010051696 Growth Hormone Proteins 0.000 title 1
- 239000000122 growth hormone Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 16
- 229920006395 saturated elastomer Polymers 0.000 abstract 15
- 229910052757 nitrogen Inorganic materials 0.000 abstract 12
- 229910052760 oxygen Inorganic materials 0.000 abstract 12
- 229910052717 sulfur Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- -1 1H-tetr azole-5-yl Chemical group 0.000 abstract 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 9
- 239000001301 oxygen Substances 0.000 abstract 9
- 239000011593 sulfur Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 8
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 150000001721 carbon Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5079097P | 1997-06-25 | 1997-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4950621A1 true CO4950621A1 (es) | 2000-09-01 |
Family
ID=21967444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98036379A CO4950621A1 (es) | 1997-06-25 | 1998-06-25 | Peptidos mimeticos (pirazolon-piperidinas) liberadores de la hormona del crecimiento y sus usos en el tratamiento de la resistencia a la insulina |
Country Status (40)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| US6541634B2 (en) * | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
| EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| WO2004027064A2 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CN101120138B (zh) * | 2004-12-21 | 2013-06-05 | 赫尔克里士公司 | 在含有亚硫酸盐离子的造纸体系中用作干和湿强度剂的活性阳离子树脂 |
| US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| CN101657436A (zh) | 2007-02-09 | 2010-02-24 | 特兰齐姆制药公司 | 大环生长素释放肽受体调节剂及其使用方法 |
| US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| RU2403902C1 (ru) * | 2009-06-15 | 2010-11-20 | Илья Николаевич Медведев | Способ снижения биологического возраста при нарушении толерантности к глюкозе |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| EP2852591A1 (en) | 2012-05-03 | 2015-04-01 | Novartis AG | L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| CN105164129B (zh) * | 2013-05-28 | 2018-01-19 | 拉夸里亚创药株式会社 | 多晶型物形式 |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| RU2695649C2 (ru) * | 2014-08-05 | 2019-07-25 | Раквалиа Фарма Инк. | Производные серина в качестве агонистов грелиновых рецепторов |
| TW201625613A (zh) * | 2014-10-31 | 2016-07-16 | 拉夸里亞創藥股份有限公司 | 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物 |
| WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| WO2024217441A1 (zh) * | 2023-04-21 | 2024-10-24 | 长春金赛药业有限责任公司 | GHSR 1a激动剂、药物组合物及其制备方法和应用 |
| CN119285632A (zh) * | 2024-10-09 | 2025-01-10 | 威海中腾医药科技有限公司 | 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
| US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
| CA2147503A1 (en) | 1992-11-06 | 1994-05-26 | Judith M. Pisano | Substituted dipeptide analogs promote release of growth hormone |
| WO1994013696A1 (en) | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| JPH10506091A (ja) | 1993-11-09 | 1998-06-16 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類 |
| BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
| EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| CZ195098A3 (cs) | 1995-12-22 | 1998-10-14 | Novo Nordisk A/S | Sloučeniny uvolňující růstový hormon |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/uk unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Ceased
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko not_active Ceased
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4950621A1 (es) | Peptidos mimeticos (pirazolon-piperidinas) liberadores de la hormona del crecimiento y sus usos en el tratamiento de la resistencia a la insulina | |
| ES2289787T3 (es) | Administracion en larga duracion en embolada de d-treo-metilfenidato. | |
| AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
| AR044527A1 (es) | Prodrogas 2' y3' de nucleosidos modificados para tratar flaviviridae | |
| AR082391A1 (es) | Inhibidores biciclicos de acetil-coa y usos de los mismos | |
| AR041913A1 (es) | Formulaciones de deposito de liberacion controlada | |
| PE20080234A1 (es) | Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| KR930700490A (ko) | 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드 | |
| AR043101A1 (es) | Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina para el tratamiento de infecciones de flaviviridae, sus usos en la manufactura de medicamentos y metodos para el tratamiento de infecciones de flaviviridae | |
| RU2004110719A (ru) | Зздабиторы протеаз, расщепляющих за пролином | |
| AR003947A1 (es) | Utilizacion de una cantidad efectiva de como minimo un compuesto de tipo retinoide como agente activo en una composicion cosmetica o para la fabricacionde una composicion farmaceutica, y compuestos especificos de dicho tipo. | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| PE32296A1 (es) | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables | |
| SV2002000969A (es) | Composicion parenteral reconstituible | |
| AR034396A1 (es) | Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| JP2019163275A (ja) | 特定の標的集団におけるアルコール消費を低減するためのナルメフェン | |
| AR047962A1 (es) | Combinacion de agonistas de adrenoceptor beta-2 y corticosteroides para el tratamiento de enfermedades respiratorias | |
| AR013503A1 (es) | Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion | |
| AR031857A1 (es) | Pirroloquinolonas, composiciones farmaceuticas, uso de las mismas para preparar un medicamento antiviral y un metodo para producir un intermediario | |
| RU2017133660A (ru) | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций | |
| AR074700A1 (es) | Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades | |
| AR062979A1 (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina |